{"title":"GLP-1 受体激动剂在控制糖尿病相关并发症方面的疗效：综述。","authors":"Mahshad Gholami, Narges Zargar Balajam, Samira Rakhsha, Sayed Mahmoud Sajjadi-Jazi, Gita Shafiee, Ramin Heshmat","doi":"10.1007/s40200-025-01604-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Diabetes mellitus (DM) is often accompanied by various comorbidities, including cardiovascular diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), renal dysfunction, polycystic ovary syndrome (PCOS), neurological disorders, psychiatric conditions, and others. These comorbidities complicate diabetes management and contribute to worsened health outcomes. This narrative review explores the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in managing a broad range of diabetes-related comorbidities, assessing their therapeutic potential beyond glycemic control.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, and Web of Science. Additionally, AI-based tools like ChatGPT were employed from <b>September 2024 to January 2025</b> to enhance the accuracy of data collection and analysis. The search was conducted using keywords such as \"GLP-1 receptor agonists\", \"diabetes and comorbidities\", \"cardiovascular diseases\", \"MASLD\", \"renal dysfunction\", \"PCOS\", \"neurological disorders\", \"psychiatric disorders\", \"sleep apnea\", \"osteoarthritis\", and \"diabetic retinopathy\". Boolean operators (AND/OR) were used to combine the keywords for efficient searching. Studies were selected and analyzed based on predefined criteria to evaluate the efficacy of GLP-1 receptor agonists (GLP1RAs) in managing diabetes-related comorbidities.</p><p><strong>Results: </strong>GLP1RAs have demonstrated significant benefits in managing various comorbidities, including cardiovascular diseases, liver conditions (such as MASLD), renal dysfunction, and metabolic disorders like PCOS. They also show promise in addressing neurological and psychiatric disorders, likely due to their anti-inflammatory, neuroprotective, and metabolic effects.</p><p><strong>Conclusion: </strong>GLP1RAs offer a multifaceted approach to treating not only diabetes but also its associated comorbidities, improving patient outcomes across multiple health domains. However, further research is required to confirm these benefits and optimize treatment strategies for diverse patient populations.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01604-w.</p>","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 1","pages":"92"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961817/pdf/","citationCount":"0","resultStr":"{\"title\":\"GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.\",\"authors\":\"Mahshad Gholami, Narges Zargar Balajam, Samira Rakhsha, Sayed Mahmoud Sajjadi-Jazi, Gita Shafiee, Ramin Heshmat\",\"doi\":\"10.1007/s40200-025-01604-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Diabetes mellitus (DM) is often accompanied by various comorbidities, including cardiovascular diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), renal dysfunction, polycystic ovary syndrome (PCOS), neurological disorders, psychiatric conditions, and others. These comorbidities complicate diabetes management and contribute to worsened health outcomes. This narrative review explores the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in managing a broad range of diabetes-related comorbidities, assessing their therapeutic potential beyond glycemic control.</p><p><strong>Methods: </strong>A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, and Web of Science. Additionally, AI-based tools like ChatGPT were employed from <b>September 2024 to January 2025</b> to enhance the accuracy of data collection and analysis. The search was conducted using keywords such as \\\"GLP-1 receptor agonists\\\", \\\"diabetes and comorbidities\\\", \\\"cardiovascular diseases\\\", \\\"MASLD\\\", \\\"renal dysfunction\\\", \\\"PCOS\\\", \\\"neurological disorders\\\", \\\"psychiatric disorders\\\", \\\"sleep apnea\\\", \\\"osteoarthritis\\\", and \\\"diabetic retinopathy\\\". Boolean operators (AND/OR) were used to combine the keywords for efficient searching. Studies were selected and analyzed based on predefined criteria to evaluate the efficacy of GLP-1 receptor agonists (GLP1RAs) in managing diabetes-related comorbidities.</p><p><strong>Results: </strong>GLP1RAs have demonstrated significant benefits in managing various comorbidities, including cardiovascular diseases, liver conditions (such as MASLD), renal dysfunction, and metabolic disorders like PCOS. They also show promise in addressing neurological and psychiatric disorders, likely due to their anti-inflammatory, neuroprotective, and metabolic effects.</p><p><strong>Conclusion: </strong>GLP1RAs offer a multifaceted approach to treating not only diabetes but also its associated comorbidities, improving patient outcomes across multiple health domains. However, further research is required to confirm these benefits and optimize treatment strategies for diverse patient populations.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s40200-025-01604-w.</p>\",\"PeriodicalId\":15635,\"journal\":{\"name\":\"Journal of Diabetes and Metabolic Disorders\",\"volume\":\"24 1\",\"pages\":\"92\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961817/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes and Metabolic Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40200-025-01604-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-025-01604-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
目的：糖尿病（DM）通常伴有各种合并症，包括心血管疾病、代谢功能障碍相关脂肪变性肝病（MASLD）、肾功能障碍、多囊卵巢综合征（PCOS）、神经系统疾病、精神疾病等。这些合并症使糖尿病管理复杂化，并导致健康结果恶化。本综述探讨了胰高血糖素样肽-1 （GLP-1）受体激动剂在管理广泛的糖尿病相关合并症中的疗效，评估了它们在血糖控制之外的治疗潜力。方法：通过检索PubMed、Scopus、Web of Science等科学数据库，对相关文献进行综合综述。此外，从2024年9月到2025年1月，使用了ChatGPT等基于人工智能的工具来提高数据收集和分析的准确性。搜索关键词包括“GLP-1受体激动剂”、“糖尿病及合并症”、“心血管疾病”、“MASLD”、“肾功能障碍”、“多囊卵巢综合征”、“神经系统疾病”、“精神疾病”、“睡眠呼吸暂停”、“骨关节炎”和“糖尿病视网膜病变”。布尔运算符（AND/OR）用于组合关键字，以提高搜索效率。根据预定义的标准选择和分析研究，以评估GLP-1受体激动剂（GLP1RAs）在管理糖尿病相关合并症中的功效。结果：GLP1RAs在治疗各种合并症方面显示出显著的益处，包括心血管疾病、肝脏疾病（如MASLD）、肾功能障碍和代谢紊乱（如多囊卵巢综合征）。它们在治疗神经和精神疾病方面也表现出希望，可能是由于它们的抗炎、神经保护和代谢作用。结论：GLP1RAs提供了一种治疗糖尿病及其相关合并症的多方面方法，改善了患者在多个健康领域的预后。然而，需要进一步的研究来证实这些益处，并针对不同的患者群体优化治疗策略。补充信息：在线版本包含补充资料，提供地址：10.1007/s40200-025-01604-w。
GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review.
Objectives: Diabetes mellitus (DM) is often accompanied by various comorbidities, including cardiovascular diseases, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), renal dysfunction, polycystic ovary syndrome (PCOS), neurological disorders, psychiatric conditions, and others. These comorbidities complicate diabetes management and contribute to worsened health outcomes. This narrative review explores the efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in managing a broad range of diabetes-related comorbidities, assessing their therapeutic potential beyond glycemic control.
Methods: A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, and Web of Science. Additionally, AI-based tools like ChatGPT were employed from September 2024 to January 2025 to enhance the accuracy of data collection and analysis. The search was conducted using keywords such as "GLP-1 receptor agonists", "diabetes and comorbidities", "cardiovascular diseases", "MASLD", "renal dysfunction", "PCOS", "neurological disorders", "psychiatric disorders", "sleep apnea", "osteoarthritis", and "diabetic retinopathy". Boolean operators (AND/OR) were used to combine the keywords for efficient searching. Studies were selected and analyzed based on predefined criteria to evaluate the efficacy of GLP-1 receptor agonists (GLP1RAs) in managing diabetes-related comorbidities.
Results: GLP1RAs have demonstrated significant benefits in managing various comorbidities, including cardiovascular diseases, liver conditions (such as MASLD), renal dysfunction, and metabolic disorders like PCOS. They also show promise in addressing neurological and psychiatric disorders, likely due to their anti-inflammatory, neuroprotective, and metabolic effects.
Conclusion: GLP1RAs offer a multifaceted approach to treating not only diabetes but also its associated comorbidities, improving patient outcomes across multiple health domains. However, further research is required to confirm these benefits and optimize treatment strategies for diverse patient populations.
Supplementary information: The online version contains supplementary material available at 10.1007/s40200-025-01604-w.
期刊介绍：
Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
